October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
April 2012 in “The Journal of Urology” Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
[object Object]
3 citations,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
February 2007 in “Lancet Oncology” Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.
April 2012 in “The Journal of Urology” More prostate biopsies increase the chance of finding cancers that may not need treatment.
12 citations,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
[object Object]
9 citations,
July 2018 in “Medicine” Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.
April 2012 in “The Journal of Urology” Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
6 citations,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
14 citations,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
1 citations,
August 2021 in “Preventive Medicine” Not taking prescribed medications properly can lead to higher death rates from unrelated health conditions.
October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
13 citations,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
5 citations,
March 2005 in “Current Urology Reports” Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
20 citations,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
56 citations,
April 1998 in “Steroids” Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.
30 citations,
January 2023 in “EFSA journal” Adults should not consume more than 255 micrograms of selenium per day to avoid risk of hair loss and other side effects.
7 citations,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
4 citations,
November 2005 in “The Journal of Urology” Large prostates link to more hair loss.
7 citations,
October 2017 in “The Prostate” Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.
88 citations,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” Minoxidil and finasteride effectively treat hair loss.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.